The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- NovelMed Therapeutics Inc., a ...

To be rolled out in January 2027, the track will replace Tech.Pass as part of broader foreign workforce refinements the Ministry is introducing.

New training materials for maintenance technicians include 3D models and video instruction. LONDON, UNITED KINGDOM, ...

America’s power grid is aging into obsolescence. Much of the infrastructure that keeps the lights on today was constructed in ...

The spirit of innovation is transforming industries across the region, as organizations implement creative, high-value solutions to address complex problems. From tackling rural workforce shortages to ...

The new silos will include 24 new forward launch centers, three centralized wing command centers, and more than 5,000 miles ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

Looking for alternatives to Profound AI? Discover top tools in 2026 to optimize and monitor your brand’s visibility across AI-driven search experiences.

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.

In Paris, culture and tourism are key priorities for the city government and are now taking center stage in the 2026 municipal campaign. Support for cultural players, management of municipal venues, ...

The best Apple Watch alternatives offer many of the features you love about Apple’s wearables, including an accurate GPS, durable build, helpful smart integrations, excellent fitness tracking, and ...

When an AI system in health care gives a confident answer, should clinicians trust it? In a new article from Frontiers in ...